APRICUS BIOSCIENCES TO PRESENT AT THE PRECISIONIR INFORMED INVESTORS FORUM BIOTECH, HEALTHCARE AND PHARMA VIRTUAL CONFERENCE ON OCTOBER 13
San Diego, CA, October 11, 2010 --Apricus Biosciences ("Apricus Bio") (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that Bassam Damaj, Ph.D., President and Chief Executive Officer, will present at PrecisionIR's Informed Investors Forum Biotech, Healthcare and Pharma Virtual Conference on October 13, 2010 at 12:00pm Eastern time.
Interested parties can access the audio webcast with slide presentation at http://www.vcall.com/customevent/conferences/biotech/20101013/index.html.
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com.
Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development Apricus Bio, Inc.
Apricus Bio Investor Relations
Apricus Bio, Inc. Rx Communications Group, LLC